Wednesday, May 3, 2017

INVIVOSCRIBE® RECEIVES FDA APPROVAL FOR THE LEUKOSTRAT® CDX FLT3 MUTATION ASSAY COMPANION DIAGNOSTIC TEST FOR THE SELECTION OF PATIENTS FOR RYDAPT® AND IS THE FIRST COMPANION DIAGNOSTIC FOR AML

INVIVOSCRIBE® RECEIVES FDA APPROVAL FOR THE LEUKOSTRAT® CDX FLT3 MUTATION ASSAY COMPANION DIAGNOSTIC TEST FOR THE SELECTION OF PATIENTS FOR RYDAPT® AND IS THE FIRST COMPANION DIAGNOSTIC FOR AML
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)